# US 2015/0104864 A1 · Method for generating cancer stem cells from immortalized cell lines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104864 A1
- Document ID: US20150104864A1
- Status: Published application
- Kind: A1
- Application number: 14/222,697
- Filed: 2014-03-24
- Published: 2015-04-16
- Earliest claimed: 2013-10-11
- Assignees: Korea University Research and Business Foundation
- Applicants: Korea University Research and Business Foundation
- Inventors: Sunghoi Hong; Seung-Ick Oh; Hang-Soo Park
- Web page: https://patentgrep.com/patent/US20150104864A1

## CPC

- C12N 5/0695: {Stem cells; Progenitor cells; Precursor cells}
- C12N 2502/1358: Bone marrow mesenchymal stem cells (BM-MSC)
- C12N 2506/25: from renal cells, from cells of the urinary tract
- C12N 2510/04: Immortalised cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method is described for generating a novel cancer stem cell line that possesses characteristics associated with stem cells, by co-culturing a human immortalized cell line and bone marrow-derived mesenchymal stem cells, and the novel cancer stem cell line established thereby. This method is able to readily generate cancer stem cells that are low in the level of structural chromosomal aberrations and are excellent in oncogenicity, and is effectively applicable to the development of anti-cancer drugs and personalized drugs.

## Claims

### Claim 1

A method for generating a cancer stem cell line from an immortalized cell line, comprising:
co-culturing an immortalized cell line and mesenchymal stem cells in an induction medium, with the mesenchymal stem cells serving as feeder cells.

### Claim 2 (depends on 1)

The method of claim 1, wherein the induction medium comprises high-glucose DMEM having a glucose concentration in a range of from 10 to 100 mM.

### Claim 3 (depends on 2)

The method of claim 2, wherein the induction medium further comprises L-glutamine and L-alanyl-glutamine.

### Claim 4 (depends on 1)

The method of claim 1, wherein the co-culturing is carried out for a period of from 16 to 20 days.

### Claim 5 (depends on 1)

The method of claim 1, wherein the immortalized cell line comprises an HEK293 or 293FT cell line.

### Claim 6 (depends on 1)

The method of claim 1, wherein the immortalized cell line decreases in accumulated structural chromosomal aberration (chromosomal instability), or increases in chromosomal mutation by the co-culturing.

### Claim 7 (depends on 1)

The method of claim 1, wherein the cancer stem cell line possesses at least one of the following characteristics:
(a) being immunologically positive to the neural stem cell markers CD15 (SSEA-1), CD56 (NCAM), CD29 (Integrin beta1), Nestin, CD133 (Prominin 1), CD24 (Small cell lung carcinoma cluster 4 antigen) and CXCR4 (chemokine (C-X-C motif) receptor 4); and negative to the mesenchymal stem cell marker CD73 (Ecto-5′-Nucleotidase);
(b) no appearance of differentiated cells upon suspension culture;
(c) the appearance of dendrites, morphologically characteristic of neural cells, having round and streamlined nuclei that are large in comparison to whole cells in an FBS-supplemented medium;
(d) the oncogenicity that even as few as 10 cells can form tumor in immune-suppressed mice (BALE/c nu/nu); and
(e) differentiation into neural cells in an induction medium.

### Claim 8 (depends on 7)

The method of claim 7, wherein the cancer stem cell line is maintained for an extended period of time by a plurality of passages in an adherent culture manner in a medium supplemented with FBS.

### Claim 9 (depends on 7)

The method of claim 7, wherein the cancer stem cell line is maintained for a an extended period of time by a plurality of passages in a suspension culture without manner in a medium devoid of FBS.

### Claim 10 (depends on 9)

The method of claim 9, wherein the medium devoid of FBS further comprises bFGF and EGF.

### Claim 11 (depends on 9)

The method of claim 9, wherein CD133, serving as a marker for neural stem cells, is expressed at an elevated level by the suspension culture, thus making CD15+/CD133+ cells account for more than 90% of total cell counts.

### Claim 12 (depends on 1)

A cancer stem cell line, generated using the method of claim 1.

### Claim 13

A culture medium for inducing a cancer stem cell line from an immortalized cell line, comprising:
mesenchymal stem cells; and
high-glucose DMEM supplemented with FBS, L-glutamine, and L-alanyl-glutamine.
